pharmaphorum2d
Ipsen's rare disease drug palovarotene knocked back in EU
Palovarotene was acquired by Ipsen as part of its $1 billion upfront acquisition of Clementia Pharma in 2019, but almost immediately ran into trouble. It failed a futility test in a pivotal trial ...
pharmaphorum5d
After FDA setback, Ipsen gets first OK for rare disease drug palovarotene
a rare disease therapy acquired via its $1.3 billion takeover of Clementia Pharma in 2019. Health Canada has given the drug a green light – under the Sohonos brand – to treat fibrodysplasia ...